Table 2.
Summary of Clinical Trials related to mucormycosis[25]
| ClinicalTrials.gov Identifier | Sponsor | Condition | Phase | Study Type | Intervention/Treatment |
|---|---|---|---|---|---|
| NCT03816176 | Astellas Pharma Inc | Invasive Mucormycosis | Phase 2 | Intervention | Isavuconazonium sulfate |
| Invasive Aspergillosis | |||||
| NCT03387696 | University Hospital, Grenoble | Mucormycosis | Not Applicable | Observational | Not Applicable |
| NCT02226705 | Assistance Publique - Hôpitaux de Paris | Rhinocerebral Mucormycosis | Not Applicable | Interventional | Procedure: Multiple transnasal endoscopic surgeries |
| NCT04502381 | Postgraduate Institute of Medical Education and Research | Pulmonary Mucormycosis | Phase 2 | Interventional | Drug: Inhaled amp B deoxycholate + intravenous liposomal amp B |
| Drug: Intravenous liposomal amphotericin B alone | |||||
| NCT00419770 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical center | Mucormycosis | Phase 2 | Interventional | Drug: deferasirox |
| Drug: Placebo | |||||
| Drug: Liposomal amphotericin B | |||||
| NCT04550936 | Pfizer | Invasive Aspergillosis Mucormycosis |
Not Applicable | Observational | Drug: Isavuconazole |
| NCT04744454 | Pfizer | Aspergillosis | Post Marketing Surveillance (PMS) Study | Observational | Drug: Isauvuconazole group |
| Mucormycosis | |||||
| NCT00467883 |